Pharmacogenomic‐based personalized medicine: Multistakeholder perspectives on implementational drivers and barriers in the Canadian healthcare system
Abstract Pharmacogenomics (PGx)‐based personalized medicine (PM) is increasingly utilized to guide treatment decisions for many drug‐disease combinations. Notably, London Health Sciences Centre (LHSC) has pioneered a PGx program that has become a staple for London‐based specialists. Although impleme...
Guardado en:
Autores principales: | Mathushan Subasri, David Barrett, Jovana Sibalija, Lisa Bitacola, Richard B. Kim |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Wiley
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/eafb2eb5f6264a2591f92a50e7f25a9b |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Pharmacogenomics and Personalized Medicine
Publicado: (2009) -
Barriers and Facilitators to Resuming In-Person Psychotherapy with Perinatal Patients amid the COVID-19 Pandemic: A Multistakeholder Perspective
por: Nicole Andrejek, et al.
Publicado: (2021) -
Pharmacogenomics and Personalized Medicine in Type 2 Diabetes Mellitus: Potential Implications for Clinical Practice
por: Venkatachalapathy P, et al.
Publicado: (2021) -
Systematic pharmacogenomics analysis of a Malay whole genome: proof of concept for personalized medicine.
por: Mohd Zaki Salleh, et al.
Publicado: (2013) -
Analytics of the clinical implementation of pharmacogenomics testing in 12 758 individuals
por: Yang Wang, et al.
Publicado: (2021)